Company news

Emyria Ltd news in 2022

Emyria Ltd's news releases, calls and decks from 2022, newest first.

View company

Emyria accepted into National Institutes of Health Program

November 27, 2022

Placement completion and secondary trading notice

November 22, 2022

Emyria completes $3m placement

October 30, 2022

Emyria and UWA expand unique MDMA-inspired analogue library

October 17, 2022

Emyria expands clinical sites for EMD-RX5 Phase 3 trial

September 25, 2022

Emyria commences US preclinical program for MDMA library

September 19, 2022

Appendix 4E and Annual Report

August 29, 2022

Positive results received for Emyrias MDMA-inspired program

August 17, 2022

Emyria receives ethics approval for EMD-RX5 Phase 3 trial

August 16, 2022

Preclinical studies initiated for MDMA-inspired analogues

August 4, 2022

Appendix 4C - Quarterly

July 27, 2022

Emyria expands drug candidate library inspired by MDMA

July 17, 2022

Emyria expands MDMA analogue program with UWA

May 31, 2022

EMD-RX5 demonstrates excellent safety and bioavailability

May 24, 2022

Further positive MDMA analogue screening results received

May 9, 2022

Broker Briefing Presentation

March 24, 2022

Emyria launches second ultra-pure CBD capsule

March 16, 2022

Recruitment commenced for EMD-RX5 Phase 1 Study

March 8, 2022

Ethics approval received for EMD-RX5 Phase 1 Study

March 3, 2022

Emyria grows its novel MDMA-analogue library

February 21, 2022

Application for quotation of securities - EMD

February 13, 2022

Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD

January 19, 2022

Decks in 2022